Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness

Phase 4

Completed

• Conditions: Asthma
• Interventions: Drug: placebo; Drug: ipratropium bromide

• Registration Number: NCT00605410
• Lead Sponsor: University of Saskatchewan

Brief Summary

Certain lung disease medications can influence diagnostic tests and research investigations. This study will investigate how long ipratropium bromide must be withheld before a methacholine challenge test can be conducted. This information will be useful for validating current guidelines.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01
• Study First Submitted: 2008-01-18
• Study First Submitted QC: 2008-01-30
• Study First Posted: 2008-01-31
• Primary Completion: 2008-04
• Study Completion: 2008-04
• Status Verified: 2008-07
• Last Update Submitted: 2009-01-06
• Last Update Posted: 2009-01-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Diagnosis of asthma; stable and controlled
• FEV1 greater than or equal to 65% predicted

Exclusion Criteria

• Concomitant lung disease other than asthma

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
2	placebo	-
1	ipratropium bromide	-

Primary Outcome Measures

Name	Time	Method
methacholine PC20	6hours and 12 hours post inhalation

Trial Locations

Locations (1)

University of Saskatchewan; 🇨🇦 Saskatoon, Saskatchewan, Canada